EVALUATION OF LIVER FAT AND FIBROSIS WITH FIBROSCAN IN CELIAC PATIENTS

Aims The aim of this study is to determine the fibrosis and adiposity scores with Fibroscan, a noninvasive method in celiac patients,and to determine the factors affecting them.

Methods Measurements were made with the Fibro Scan device (Echosens,France) using the M probe of 45 patients who were followed up in our outpatient clinic with the diagnosis of celiac disease(serology+histopathology) and had no known liver disease other than celiac disease.Controlled Attenuation Parameter(CAP score) values were measured in order to evaluate liver fibrosis measurements and hepatic steatosis.

Results 75.6%(34) of the patients were female.The mean diagnosis of celiac disease was 97.87±84.39 months.The mean age of the patients was42±12.13 years.The mean body mass index(BMI) was 23.88±4.17 kg/m2.The mean TG of the patients was 117.79±69.64 mg/dl,AST mean 21.48±10.27 U/L,ALT mean 22.35±15.30 U/L,ALP mean 75.62±24.55 U/L,GGT mean 14.53±9.63 U/L.The mean HGB was 12.9±1.5 g/dl.The patients' mean liver fibrosis score was 6.02±10.62 kPa,and the mean CAP score was 224.96±51.19dB/m(min140,max 360 dB/m).According to CAP values,71% of the patients were classified as Stage 0, 11% as Stage 1, 3% as Stage 2, and 15% as Stage 3 fatty liver.There was no statistically significant difference according to gender in CAP value and fibroscan fibrosis scores.A positive correlation was found between CAP score and BMI,LDL,TG,and GGT(p<0.005).

Conclusions According to the CAP score of celiac patients, one third of them had stage 1 and higher fatty liver.A statistically significant correlation was found between CAP score and GGT,TG,andLDL.

Publication History

Article published online:
14 April 2022